ReGrow Fuel
A 5-alpha reductase inhibitor-free formula for patients who want to avoid finasteride/dutasteride side effects, combining oral minoxidil with GHK-Cu, apigenin, and fisetin.
No commitment · Cancel anytime · Physician evaluation required
Overview
A 5-alpha reductase inhibitor-free formula for patients who want to avoid finasteride/dutasteride side effects, combining oral minoxidil with GHK-Cu, apigenin, and fisetin.
This formulation is compounded by a licensed 503A pharmacy pursuant to an individual prescription following a physician evaluation.
How It's Used
Your prescribing physician will determine the appropriate starting dose and tier based on your health history, current medications, and treatment goals. Follow your physician's specific instructions — do not adjust dose or frequency on your own.
Safety & Considerations
Minoxidil, taken orally, can cause fluid retention, rapid heart rate, and unwanted hair growth on areas beyond the scalp (face, body). Patients with heart conditions should be screened before use. Discontinuing minoxidil typically reverses any regrowth gained. Oral minoxidil is FDA-approved only for severe hypertension — its use for hair loss, at low doses, is off-label, though well-established in dermatology practice.
Compounded Medication Disclosure
These statements have not been evaluated by the Food and Drug Administration. This product is not FDA-approved, has not been evaluated by the FDA for safety, effectiveness, or quality, and is not represented as a generic or equivalent version of any FDA-approved drug.
References
This is a compounded, multi-ingredient formulation and, as such, has not itself been studied in dedicated clinical trials. The references below are the FDA prescribing information (or, where noted, peer-reviewed literature) for each individual active ingredient in this formulation. Ask your physician for further ingredient-specific information.
- Characterization and Management of Adverse Events of Low-Dose Oral Minoxidil Treatment for Alopecia: A Narrative Review
MDPI Journal of Clinical Medicine, 2025